Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
157.10
+0.44 (0.28%)
At close: Jun 13, 2025, 4:00 PM
157.14
+0.04 (0.03%)
After-hours: Jun 13, 2025, 7:55 PM EDT
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
$646,857
Profits / Employee
$157,929
Market Cap
377.99B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
JNJ News
- 23 hours ago - Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma - PRNewsWire
- 1 day ago - New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia - PRNewsWire
- 2 days ago - Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis - PRNewsWire
- 3 days ago - Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors - Business Wire
- 7 days ago - Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? - Market Watch
- 10 days ago - DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity - PRNewsWire
- 10 days ago - Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients - PRNewsWire